Table 1 Patients’ characteristics, treatment and response to anti-EGFR agents

From: HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients

Patients ( N =170)

Age (years)

  

 Mean±s.d.

60±11

 

 Median

62

 

 Range

28–76

 
 

Number of cases

Percentage (%)

Sex

  

 Male

102

60

 Female

68

40

Regimens

  

 Cetuximab or panitumumab

12

7

 Cetuximab+chemotherapy

158

93

Response ( N =158)

  

 Complete response

3

2

 Partial response

53

33

 Non-responders

102

65

  1. Abbreviation: EGFR, epidermal growth factor receptor.
Back to article page